TB-500 10mg (Thymosin Beta-4)

TB-500 is a 43 amino acid synthetic analogue of thymosin beta-4 (TB-4), a protein found naturally in nearly all mammalian cells. What it is known for is its effect on actin protein, on cell migration and on wound healing. Animal models and in vitro studies report improved blood vessel growth, accelerated wound healing, decreased inflammation and increased extracellular matrix production. The peptide is under current investigation for its ability to reduce oxidative stress in spinal cord injury, to improve recovery following a heart attack, and for its many anti-ageing effects.

TB-500 is the synthetic N-acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, corresponding to residues 17 to 23 of thymosin beta-4. It is not thymosin beta-4 itself. Thymosin beta-4 is a 43 residue protein and one of the most abundant intracellular proteins in mammalian cells; TB-500 is the short fragment containing the actin-binding motif that carries much of the extracellular activity.

The parent protein's primary intracellular role is sequestering monomeric G-actin, holding a reserve pool that can be released for filament assembly when a cell needs to move or remodel. The LKKTET motif is the part of the sequence responsible for that actin interaction, and work defining the biological activities of thymosin beta-4 by short peptide sequences established that fragments containing this motif reproduce several of the parent protein's extracellular effects.

Extracellularly, thymosin beta-4 has been reported to promote endothelial cell migration and angiogenesis, to reduce inflammatory signalling, and in cardiac work to activate integrin-linked kinase and Akt signalling with improved cardiomyocyte survival and migration after injury. Whether the heptapeptide fully reproduces each of these is not uniformly established, which is the central caveat of the fragment approach.

TB-500 is the active domain of TB-4, whose primary role is as an actin binding protein. Actin is a critical component of cell structure and is what microfilaments are made of. Microfilaments give cells their shape, protect the integrity of cell membranes, allow cells to move and migrate, and carry out certain steps in cellular reproduction. Actin is also one of the primary components of muscle protein; without it, muscles could not contract. Actin binding proteins such as TB-4 sequester actin monomers, the individual units of actin, which protects them from degradation and keeps them available for polymerization into microfilaments when they are needed.

Research in rats has found that TB-500 encourages central and peripheral nervous system tissues to repair and remodel following injury. The exact mechanism has yet to be elucidated, but the research indicates that the peptide activates the cells that support neurons. Those cells, called oligodendrocytes, keep neurons healthy, and boosting their activity improves both blood vessel and neuron growth in brain regions that have been damaged. That significant laboratory result is reflected in clinically significant improvements in behavior, motor control and cognitive measurements.

Recent research shows that TB-500 can reduce oxidative stress following spinal cord injury and help transplanted neural stem and progenitor cells (NSPCs) survive long enough to enhance spinal regeneration. Findings like these could make TB-500 and other TB-4 derivatives of great use in treating severe spinal cord injury, and may offer critical insight into the kind of spinal recovery that would allow paralyzed individuals to regain use of affected body regions.

TB-500 and TB-4 are both potent stimulators of VEGF expression. VEGF is an important signalling molecule in the growth of capillaries, the small blood vessels that everything from wound healing to hair growth depends on. The role of TB-500 is thought to be more complicated than that alone. It likely underpins a number of steps in the process of blood vessel growth, including extracellular matrix remodeling, vasculogenesis, angiogenesis, and the transition of more primitive mesenchymal tissue into the specialized endothelial tissue that lines blood vessels. That speculation rests on something concrete: loss of TB-4 has been shown to interfere with blood vessel growth and stability, while exogenous administration improves capillary formation and the recruitment of pericytes following injury.

The discovery that TB-500 improves hair growth happened by accident. Mice genetically deficient in TB-4 were shaved for laboratory experiments, and their hair was observed to grow back much more slowly than that of wild-type animals. When the same scientists investigated hair growth in mice genetically modified to produce increased levels of TB-4, they found that their hair grew back much faster than normal. Under the microscope, those mice show increased numbers of hair shafts and grouped hair follicles.

Multi-drug resistance is becoming increasingly common across a number of infections, rendering current therapy ineffective. There are very few new antibiotics in the pipeline and the process of drug development can take upwards of twenty years on average, so a recent study on the effects of TB-4 and its adjuvants provides some hope. In mice suffering a Pseudomonas aeruginosa infection of the eye, TB-4 combined with ciprofloxacin, the standard antibiotic for treating that organism, increased the effects of the antibiotic, improved healing, reduced inflammation and promoted faster recovery. Just five days of combined therapy showed decreased numbers of colony forming units (CFUs), a decreased neutrophil count and decreased levels of inflammatory reactive oxygen species. It is the first study to demonstrate that TB-500 and similar peptides might be used to promote and enhance the effects of antibiotics.

Two decades of research have shown a number of beneficial effects for TB-4 and its derivatives in the cardiovascular and renal systems, though the exact mechanisms behind those contributions are not clearly understood. Several appear to be at work at once. TB-500 promotes the growth of collateral blood vessels, which is useful both as a preventative and in restoring function following disease. It encourages endothelial cell migration and myocyte survival following a heart attack. And it appears to work in concert with other natural signalling molecules to reduce inflammation and reduce fibrosis, meaning scar formation.

More recently, research into hydrogels containing a combination of collagen and TB-4 has shown the peptide promoting angiogenesis and epicardial heart cell migration, which boosts rates of recovery following ischemia and helps prevent long-term complications by reducing scarring.

Progress in finding a treatment for neurodegenerative diseases like Alzheimer's and prion disease has been slow at best. A recent study into the effects of TB-4 on the immune system's ability to deal with prion protein has shown that the peptide enhances autophagy. Autophagy is the central nervous system's primary protective mechanism against neurodegenerative disease, and the ability of TB-4 to enhance that natural immunity is the first progression toward real treatment of these debilitating diseases in a long time.

This is the single most important thing to establish before reading anything else about this compound. Thymosin beta-4 is a 43 residue protein of about 4963 daltons. TB-500 as supplied is normally the acetylated heptapeptide Ac-LKKTETQ, roughly 889 daltons. They are different molecules with a fivefold difference in mass.

The confusion is compounded by CAS numbering. CAS 77591-33-4 designates thymosin beta-4, the full-length protein. A certificate that quotes that CAS number alongside a mass near 889 daltons is internally inconsistent: it names one molecule and reports another. That inconsistency is checkable in seconds and is one of the most common documentation errors in this corner of the market.

The practical rule is to read the reported mass rather than the name. A mass spectrum is the fastest way to establish which of the two molecules is actually present, because the two cannot be confused on mass.

The cardiac work, the ophthalmic clinical trials and the stem cell and autophagy studies were conducted with thymosin beta-4, not with the heptapeptide. That matters because the fragment was chosen on the basis that the LKKTET motif carries the actin-binding activity, and work on short peptide sequences supports the idea that fragments reproduce several of the parent's extracellular effects.

Supports is not the same as establishes for every effect. Some activities of the parent protein depend on regions outside residues 17 to 23, and the assumption that a heptapeptide reproduces the full pharmacology of a 43 residue protein is an inference rather than a demonstrated equivalence.

Reading the literature accurately therefore means noting, for each finding, which molecule was actually administered. A result obtained with the full protein is evidence about the full protein first and about the fragment only by extrapolation.

The strongest human evidence for this molecular family is ophthalmic. Randomised, placebo-controlled phase 2 trials of thymosin beta-4 ophthalmic solution reported improvement in signs and symptoms of severe dry eye. Those trials used a topical formulation of the full-length protein in an eye indication.

There is no approved product containing either molecule in any jurisdiction, and no adequately powered human trial supporting the musculoskeletal repair uses most often discussed for TB-500. Material supplied for research is for in-vitro laboratory use only and is not a medicine.

The heptapeptide is short, highly charged from two lysines and a glutamate, and freely water-soluble. Its small size makes mass confirmation straightforward, which is precisely why the mass on a certificate is the most useful single field for this compound.

The N-terminal acetylation is part of the specification rather than an optional detail: the free-amine heptapeptide is a different molecule with a mass 42 daltons lower. A certificate reporting the unacetylated mass is describing an impurity or a different product, not the intended one.